/Companies

Engage Bio

AcquiredYC W22

San Francisco, US · Founded 2021 · 10 employees · 17 known investors

Find your way into Engage Bio

Sign up to see every warm intro you have to Engage Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Engage Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

Also known as Engage Biologics Inc.

Founders & leadership· Y Combinator alumni (W22)

Engage Bio was founded in 2021 by Will Olsen.

WOWill Olsen
Will OlsenFounderWill Olsen is co-founder and CEO of Engage Bio.
KK
Kathryn Kwant

Investors · 17

CAL Innovationlisted by CAL InnovationMill Valley

How we know: Y Combinator's founder network · Not right? Tell us

SciFounderslisted by SciFoundersSan Francisco · $1M

How we know: funding news · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

10X CapitalreportedNew York

How we know: Y Combinator's founder network · Not right? Tell us

AJGreported

How we know: Y Combinator's founder network · Not right? Tell us

Forward Deployed VCreported

How we know: Y Combinator's founder network · Not right? Tell us

General Advancereported

How we know: Y Combinator's founder network · Not right? Tell us

Red Rooster VenturesreportedSan Mateo

How we know: Y Combinator's founder network · Not right? Tell us

SAV (Scale Asia Ventures)reportedPalo Alto

How we know: Y Combinator's founder network · Not right? Tell us

Unpopular VenturesreportedMiami · $100K – $500K

How we know: Y Combinator's founder network · Not right? Tell us

xfactor venturesreportedDedham · $100K – $200K

How we know: Y Combinator's founder network · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 7

ParcelBioParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.
Abalone BioAbalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning. The company uses large-scale biological measurement platforms and AI-powered sequence analysis to discover functional antibody drugs for pharmaceutical and biotechnology applications.
ACXACX develops bioengineered solutions for pest control in agriculture, replacing synthetic chemicals with precision biocides. The company serves crop producers and aims to enhance food security while reducing chemical dependence and promoting biodiversity.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
SynviviaSynvivia engineers molecules designed to reprogram cells. The company operates in the biotech sector.
Granza BioGranza Bio develops immunotherapy treatments leveraging naturally-occurring attack particles that are released from cytotoxic immune cells to target diseases including cancers, autoimmunity, and infections.
GentiBioGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

Companies working in the same space as Engage Bio.

Legal entities · 1

corporate structure
Engage Biologics Inc.

In the news

Frequently asked questions

What does Engage Bio do?
EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Who founded Engage Bio?
Engage Bio was founded by Will Olsen in 2021.
Who are Engage Bio's investors?
Engage Bio's investors include CAL Innovation, California Innovation Fund, Gaingels, Metaplanet, SciFounders, VentureSouq, WorldQuant Ventures, Y Combinator and 9 more.
Where is Engage Bio headquartered?
Engage Bio is headquartered in San Francisco, US.